Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma
Titel:
Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma
Auteur:
Thomas, Anne Virdee, Pradeep S. Eatock, Martin Lord, Simon R. Falk, Stephen Anthoney, D. Alan Turkington, Richard C. Goff, Matthew Elhussein, Leena Collins, Linda Love, Sharon Moschandreas, Joanna Middleton, Mark R.